Track topics on Twitter Track topics that are important to you
A more than 70% appreciation in the share price over the past two months suggests the market is recognising the potential value in Astex’s internal pipeline, particularly SGI-110 – which is the central element of Edison’s investment thesis. Despite the shares recent 52-week high, we consider there to be an attractive investment case with multiple upside catalysts. A solid Q1 with Dacogen royalty revenue of $22.1m allowed Astex to reaffirm annual royalty guidance of $55m despite the potential imminent introduction of a US generic. We value Astex at $678m (including 2013 year-end cash), equivalent to $7.25 per share basic ($6.73 diluted).
Source: Edison Investment - read full article at http://www.edisoninvestmentresearch.com/NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...